Vonoprazan fumarate for the management of acid-related diseases

References

• Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997 Jan–Feb;17(1):22–37.
   PubMed Web of Science ®Google Scholar
• Savarino V, Dulbecco P, de Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017 Jan;37:19–24.
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Shaheen NJ, Vaezi MF, American Gastroenterological Association I, Clinical P, Quality Management C. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008 Oct; 135(4):1392–1413, 413 e1–e5.
   Web of Science ®Google Scholar
• Martinucci I, de Bortoli N, Savarino E, et al. Optimal treatment of laryngopharyngeal reflux disease. Ther Adv Chronic Dis. 2013 Nov;4(6):287–301.
   PubMedGoogle Scholar
• Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009 Mar;59(3):135–153.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis. 2006;24(1–2):11–46.
   PubMed Web of Science ®Google Scholar
• Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol. 2010 Jul;26(4):367–378.
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010 Aug;59(8):1143–1153.
   PubMed Web of Science ®Google Scholar
• Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol. 2012 Mar;5(2):103–109.
   PubMed Web of Science ®Google Scholar
• Savarino E, Martinucci I, Furnari M, et al. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2016 Aug 8;1–9. [Epub ahead of print]
   PubMedGoogle Scholar
• Savarino V, Savarino E, Dulbecco P. Proton pump inhibitor failure: why does it occur and how can it be managed? Digestion. 2006;73(4):215–217.
   PubMed Web of Science ®Google Scholar
• de Bortoli N, Martinucci I, Giacchino M, et al. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. Expert Opin Drug Metab Toxicol. 2013 Oct;9(10):1361–1369.
   PubMed Web of Science ®Google Scholar
• Savarino E, Ottonello A, Martinucci I, et al. Ilaprazole for the treatment of gastro-esophageal reflux. Expert Opin Pharmacother. 2016 Oct;17(15):2107–2113.
   PubMed Web of Science ®Google Scholar
• Dutta U, Armstrong D. Novel pharmaceutical approaches to reflux disease. Gastroenterol Clin North Am. 2013 Mar;42(1):93–117.
   PubMed Web of Science ®Google Scholar
• Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015 Apr;41(7):636–648.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015 Mar;75(4):439–443.
   PubMed Web of Science ®Google Scholar
• Munson KB, Sachs G. Inactivation of H+,K+-ATPase by a K+-competitive photoaffinity inhibitor. Biochemistry. 1988 May 31;27(11):3932–3938.
   PubMed Web of Science ®Google Scholar
• Mendlein J, Sachs G. Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of H+, K(+)-ATPase. J Biol Chem. 1990 Mar 25;265(9):5030–5036.
   PubMed Web of Science ®Google Scholar
• Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005 Apr;14(4):411–421.
   PubMed Web of Science ®Google Scholar
• Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther. 2005 Dec;108(3):294–307.
   PubMed Web of Science ®Google Scholar
• Wurst W, Hartmann M. Current status of acid pump antagonists (reversible PPIs). Yale J Biol Med. 1996 May–Jun;69(3):233–243.
   PubMed Web of Science ®Google Scholar
• Simon WA, Herrmann M, Klein T, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866–874.
   PubMed Web of Science ®Google Scholar
• Ene MD, Khan-Daneshmend T, Roberts CJ. A study of the inhibitory effects of SCH 28080 on gastric secretion in man. Br J Pharmacol. 1982 Jul;76(3):389–391.
   PubMed Web of Science ®Google Scholar
• Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008 Jan;103(1):20–26.
   PubMed Web of Science ®Google Scholar
• Kim H-K, Park S-H, Cheung D-Y, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010 Oct;25(10):1618–1625.
   PubMed Web of Science ®Google Scholar
• Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011 Nov;339(2):412–420.
   PubMed Web of Science ®Google Scholar
• Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010 Oct;335(1):231–238.
   PubMed Web of Science ®Google Scholar
• Matsukawa J, Kogame A, Tagawa Y, et al. Radiographic localization study of a novel potassium-competitive acid blocker, vonoprazan, in the rat gastric mucosa. Dig Dis Sci. 2016 Jul;61(7):1888–1894.
   PubMed Web of Science ®Google Scholar
• Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145–1151.
   PubMed Web of Science ®Google Scholar
• Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015 Dec;42(11–12):1315–1326.
   PubMed Web of Science ®Google Scholar
• Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011 Jun;337(3):797–804.
   PubMed Web of Science ®Google Scholar
• Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012 May 10;55(9):4446–4456.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects–a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015 Sep;42(6):719–730.
   PubMed Web of Science ®Google Scholar
• Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016 May;43(10):1048–1059.
   PubMed Web of Science ®Google Scholar
• Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016 Apr;55(4):409–418.
   PubMed Web of Science ®Google Scholar
• Kogame A, Takeuchi T, Nonaka M, et al. Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs. Xenobiotica. 2017 Mar;47(3):255–266.
   PubMed Web of Science ®Google Scholar
• Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2016 Jul 14;1–8.
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005 Jun;20(3):153–167.
   PubMedGoogle Scholar
• Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015 Sep;42(6):685–695.
   PubMed Web of Science ®Google Scholar
• Jenkins H, Jenkins R, Patat A. Effect of multiple oral doses of the potent CYP3A4 inhibitor clarithromycin on the pharmacokinetics of a single oral dose of vonoprazan: a phase I, open-label, sequential design study. Clin Drug Investig. 2017 Mar;37(3):311–316.
   PubMed Web of Science ®Google Scholar
• Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep. 2011 Dec;13(6):540–546.
   PubMedGoogle Scholar
• Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007 Aug;12(4):317–323.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016 Jul;111(7):949–956.
   PubMed Web of Science ®Google Scholar
• Shinozaki S, Nomoto H, Kondo Y, et al. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci. 2016 May;32(5):255–260.
   PubMed Web of Science ®Google Scholar
• Yamada S, Kawakami T, Nakatsugawa Y, et al. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):550–555.
   PubMedGoogle Scholar
• Shichijo S, Hirata Y, Niikura R, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis. 2016 Oct;17(10):670–675.
   PubMed Web of Science ®Google Scholar
• Sakurai K, Suda H, Ido Y, et al. Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. WJG. 2017 Jan 28;23(4):668–675.
   PubMed Web of Science ®Google Scholar
• Noda H, Noguchi S, Yoshimine T, et al. A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. JGLD. 2016 Sep;25(3):283–288.
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Shiotani A, Katsumata R, et al. Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Dig Dis Sci. 2016 Nov;61(11):3215–3220.
   PubMed Web of Science ®Google Scholar
• Ono S, Kato M, Nakagawa S, et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017 Jan 18;22:e12374.
   PubMed Web of Science ®Google Scholar
• Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016 Sep;65(9):1439–1446.
   PubMed Web of Science ®Google Scholar
• Inaba T, Iwamuro M, Toyokawa T, et al. Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy. Aliment Pharmacol Ther. 2016 Jan;43(1):179–180.
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp. 2016;81–82:1–7.
   PubMed Web of Science ®Google Scholar
• Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016 Jan;43(2):240–251.
   PubMed Web of Science ®Google Scholar
• Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers – results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017 Jan;45(2):240–252.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Nishio E, Horio A, et al. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. J Dermatol. 2016 Mar;43(3):340–341.
   PubMed Web of Science ®Google Scholar